The need for a next-generation public health response to rare diseases

Genetics in Medicine

Volumn 19, Issue 5, 2017, Pages 489-490

  Valdez, Rodolfo ^a   Grosse, Scott D ^a   Khoury, Muin J ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONGENITAL MALFORMATION; DATA BASE; EARLY INTERVENTION; ELECTRONIC HEALTH RECORD; EMPOWERMENT; EUROPEAN UNION; GENETIC DISORDER; GOVERNMENT EMPLOYEE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HETEROZYGOSITY; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; NEWBORN SCREENING; POINT OF CARE TESTING; PRIMARY PREVENTION; PUBLIC HEALTH; PUBLIC POLICY; QUALITY OF LIFE; RARE DISEASE; SECONDARY PREVENTION; UNITED STATES; WESTERN AUSTRALIA; HIGH THROUGHPUT SEQUENCING;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PUBLIC HEALTH; RARE DISEASES;

EID: 85021747133     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.166     Document Type: Article

References (13)

1. Institute for Health Metrics and Evaluation. The Global Burden of Disease: Generating Evidence, Guiding Policy. IHME: Seattle, WA, 2013.
2. de Vrueh R, Baekelandt ERF, de Haan JMH. Priority medicines for Europe and the world: a public health approach to innovation. WHO Background Paper 6.19. Rare Diseases, 2013. http://www.who.int/medicines/areas/priority-medicines/BP6-19Rare.pdf. Accessed 16 August 2016.
3. Walker CE, Mahede T, Davis G, et al. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genet Med e-pub ahead of print 22 September, 2016.
4. Orphanet. ICD-10 coding rules for rare diseases. Orphanet procedural document, October 2014. http://www.orpha.net/orphacom/cahiers/docs/GB/Orphanet-ICD10-coding-rules.pdf. Accessed 17 October 2016
5. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study. Arch Pediatr Adolesc Med 1997;151:1096-1103.
6. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics 2006;117:923-929.
7. Dunkle M, Pines W, Saltonstall PL. Advocacy groups and their role in rare diseases research. Adv Exp Med Biol 2010; 686:515-525.
8. Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One 2015;10:e0140002.
9. Taruscio D, Vittozzi L, Stefanov R. National plans and strategies on rare diseases in Europe. Adv Exp Med Biol 2010; 686:475-491.
10. Lek M, Karczewski KJ, Minikel EV, et al.; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285-291.
11. Gahl WA, Mulvihill JJ, Toro C, et al.; UDN. The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine. Mol Genet Metab 2016;117:393-400.
12. Grosse SD, James AH, Lloyd-Puryear MA, Atrash HK. A public health framework for rare blood disorders. Am J Prev Med 2011;41(6 suppl 4):S319-S323.
13. Valdez R, Ouyang L, Bolen J. Public health and rare diseases: oxymoron no more. Prev Chronic Dis 2016;13:E05.